Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Status:
Recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
Most pediatric patients with solid tumors respond to initial high-dose, intensive therapy and
complete treatment in remission. High-risk patients however, frequently have recurrent
disease which is then treated with ad hoc regimens or early phase therapies with little
benefit to the patient. Metronomic therapy (MC), defined as lower dose continuous drug
exposure, has been successfully tested in pediatric leukemias with excellent results in terms
of improved outcome, toxicity profiles, and cost. MC has been applied to solid tumors with
little success, but has been implemented usually in the relapsed setting at a time of high
tumor burden and disease resistance.
Phase:
Early Phase 1
Details
Lead Sponsor:
Miller Children's & Women's Hospital Long Beach
Collaborators:
Children's Hospital of Orange County Children’s Hospital of Orange County